Received Mar 11, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPAB | HEP A + HEP B (TWINRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | 797F9 | — |
| HEPAB | HEP A + HEP B (TWINRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | UNK | — |
broke up with rash a month later up the torso like ringworms; has not received a second dose yet; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of rash in a 49-year-old male patient who received HAB (Twinrix) for prophylaxis. Co-suspect products included HAB (Twinrix) (batch number 797F9, expiry date 30-DEC-2025) for prophylaxis. On an unknown date, the patient received the 2nd dose of Twinrix. On 19-NOV-2024, the patient received the 1st dose of Twinrix. On an unknown date, not applicable after receiving Twinrix and 1 month after receiving Twinrix, the patient experienced rash (Verbatim: broke up with rash a month later up the torso like ringworms) and incomplete course of vaccination (Verbatim: has not received a second dose yet). The outcome of the rash was unknown and the outcome of the incomplete course of vaccination was not applicable. It was unknown if the reporter considered the rash to be related to Twinrix and Twinrix Pre-Filled Syringe Device. It was unknown if the company considered the rash to be related to Twinrix and Twinrix Pre-Filled Syringe Device. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date : 26-FEB-2025 Pharmacist called on February 26, 2025 to report a patient received the first dose for Twinrix on November 19, 2024 and broke up with rash a month later up the torso like ringworms and and had not received a second dose yet. Till the time of reporting, the patient did not receive 2nd dose of twinrix, which led to incomplete course of vaccination.